CPAP // Tag

Tag based archive
21 Sep

According to a recent Qualtrics Survey conducted September 4 though September 11, of over 200 respondents with mild to moderate sleep apnea, more than 70% said they would prefer to try the FDA-cleared Bongo Rx over traditional CPAP therapy to treat their obstructive sleep apnea when given the choice.

The Bongo Rx is a nasal device that requires no CPAP machine, CPAP mask, CPAP hose, bulky headgear, electricity or battery power.

The survey results highlight this new sleep apnea therapy device when compared to traditional CPAP machines and masks. Industry experts estimate that approximately 50% of CPAP patients on average will eventually abandon their CPAP therapy and become non-compliant.

“I feel the results of this Qualtrics Survey reflect that mild to moderate OSA sufferers want a simple and effective alternative to traditional CPAP. Over 70% of the respondents in this survey chose Bongo Rx. It’s gratifying that years of effort by our team to develop the Bongo Rx have yielded such a great outcome,” Bruce Sher, president of AirAvant Medical, maker of the Bongo Rx, says in a statement.

Credit: Source link

17 Sep

Philips announced the commercial launch of a prescription sleep position therapy device designed for patients with positional obstructive sleep apnea (OSA). The device, called the Philips NightBalance, is strapped around the abdomen and uses gentle vibrations to encourage users to alter their sleeping positions to prevent apneas.

The device includes wireless connectivity and a mobile app that monitors use and provides patients and physicians with access to data via a cloud-based system.

Multiple clinical studies have found that Philips NightBalance offers an effective, non-invasive treatment for positional OSA patients. Most recently, a study funded by Philips in the Journal of Clinical Sleep Medicine, “The POSAtive Study: Study for the Treatment of Positional Obstructive Sleep Apnea,” found that NightBalance is a non-inferior treatment to continuous positive airway pressure (CPAP) and demonstrates high adherence rates among positional OSA patients.

In the study, data showed that patients with positional OSA felt NightBalance was easier to use, easier to adjust to and more comfortable than other PAP therapy methods. Additionally, patients who used the sleep position treatment used the device for greater lengths of time compared to PAP therapy, with 74% of patients reported using NightBalance for more than four hours, compared to 64.9%.

“We are always looking to evolve our solutions to help people living with sleep apnea take control of their health,” Mark D’Angelo, sleep OSA business leader at Philips, says in a statement. “The right sleep therapy varies person-to-person, and for those who suffer from positional obstructive sleep apnea, it can be defeating when traditional therapies don’t meet their specific needs. With Philips NightBalance, positional obstructive sleep apnea patients now have a non-invasive and comfortable treatment option that can be successful, resulting in long term therapy adherence.”

Today, over 100 million people worldwide suffer from obstructive sleep apnea. From that population, it is estimated that between 36 and 47% of these patients suffer from positional OSA, a form of sleep apnea where breathing disturbances are present when sleeping on the back. Without treatment, positional OSA can cause poor sleep and fatigue, ultimately impacting a patient’s quality of life.

Philips NightBalance will be available through a prescription in the United States, United Kingdom, Austria, Germany, Switzerland, Belgium, the Netherlands and Luxembourg.

Credit: Source link

09 Sep

Compare 4 travel-friendly CPAP devices side by side. Click on the thumbnail above or “TravelCPAPGuide” to view the full matrix at a legible size, download it, or print it. Sleep Review’s matrix compares features such as dimensions, weight, noise level, interface compatibility, operating pressure range, operating modes, features, warranty, and additional information for the following devices: Breas Medical Inc Z2 Auto, Drive Devilbiss Healthcare IntelliPAP2 CPAP System, Philips DreamStation Go, and ResMed AirMini.

A version of this comparison guide is published in the August/September 2019 issue.

The dimension limit is less than 40 cm for length + width + height. Information for this guide based on data submitted by product manufacturers. Sleep Review strives for accuracy in all data but cannot be held responsible for claims made by manufacturers. All travel-friendly CPAPs may not be included. Email sroy[at] to be considered for the next update.

Print FriendlyPrint Friendly

Credit: Source link

06 Sep

Sunset Healthcare Solutions, Chicago-based manufacturer and distributor of home medical supplies, has introduced a new CPAP tube with increased flexibility and lightness.

According to a statement from the company, the redesign from Sunset comes after recurring customer concerns about tube damage. The new product, Slim CPAP Tube, features a reinforced, strain relief cuff that helps prevent stress and separation at the tube joint. The rubber grip point also helps to reduce tearing when patients attach and detach it from the CPAP machine. And the tube weighs less than others on the market, at 2.6 ounces, according to the statement issued by the manufacturer.

“We wanted to decrease the number of calls that DMEs deal with due to slim tubing not holding up or tearing,” vice president of sales, PJ Ruflin, says in a statement. “The Slim Tube should provide a more desirable product option, with durability equal to or better than most standard tubing on the market.”

Credit: Source link

05 Sep

SoClean, the company that makes devices to clean CPAP machines, has settled the $10 million lawsuit brought by a former international distributor.

The terms of the settlement between SoClean and the Australia-based distributor, SoClean 2 Pty Ltd., have not been made public, but court records show both parties requested the case be dismissed in August. The parties first informed the court in June that they were working out a settlement agreement.

SoClean 2 Pty Ltd. brought the lawsuit in the U.S. District Court in Massachusetts claiming that the Peterborough company had violated the distribution agreement by selling the devices directly to consumers.

According to the lawsuit, distributor SoClean 2 was supposed to have exclusive rights to distribute SoClean’s products in Australia, New Zealand, Singapore, Malaysia, Indonesia, the Philippines, Thailand, Japan, Hong Kong, Macau, South Korea and Taiwan.

Get the full story at

Credit: Source link

28 Aug

A new study finds that a fully-digital sleep depth measurement tool is helping experts gain a deeper understanding of sleep disorders and treatment options.

This study, published in the Journal of Clinical Sleep Medicine, looks at patients with obstructive sleep apnea using a measurement tool called the Odds Ratio Product (ORP Sleep Depth) from Cerebra to evaluate the impact of an intervention on sleep, finding sleep quality improved following continuous positive airway pressure (CPAP) treatment. It also showed that CPAP treatment has a varying effect on the sleep of the patient, indicating that some individuals may be more or less sensitive to any specific treatment approach.

“ORP Sleep Depth is an attractive measure not only in that it distills sleep depth to a single index but also because it can be obtained in an automated manner,” Charles Gerhard Penner, MD, FRCPC, lead researcher in the study, says in a statement.

Using digital sleep analysis fueled by ORP Sleep Depth, doctors can recommend and evaluate different treatment approaches for sleep apnea, based not only on their ability to open the airway, but also their impact on sleep depth and quality, according to the researchers.

Sleep measurement and analysis has traditionally required an overnight stay in a sleep lab, which meant doctors could diagnose and treat sleep apnea with limited ability to measure the impact of that treatment on sleep quality. Now, with Cerebra digital sleep analysis and ORP Sleep Depth, there is a way to measure patients’ sleep depth and quality both before and after treatment.

“Until now, management of sleep apnea, whether by CPAP or other approaches, has focused on keeping the airway open, while giving little consideration to the effect of the treatment on the person’s sleep,” says Dawson Reimer, CEO of Cerebra. “There is growing evidence that sleep itself, and not just air flow, is an important factor in caring for patients with sleep apnea.”

Credit: Source link

28 Aug

The direct-to-consumer provider of CPAP machines and supplies,, announced the launch of a newly revamped website. The new website, which is listed under the same web address, is designed to lead patients to the supplies that will best treat their disordered breathing, according to a press release from the company.

“We are excited about the new website launch and functionality it offers our customers. Our product pages offer greater detailed content as well as improved images to help CPAP users find the exact product that fits their individual needs,” Jason Crowe, Ohio Sleep Awareness CFO, says in a statement.

“The number one reason people discontinue CPAP is a lack of fit or comfort from their CPAP mask. Our new site offers detailed information, reviews and fitting guides, along with the expert support that should help any new CPAP user shop with confidence,” he says. aims to provide affordable, self-pay and HSA options for all major CPAP brands such as ResMed, Philips Respironics, and Fisher & Paykel. The website offers a selection of hundreds of CPAP masks and machines, as well as a home sleep apnea test kit.


Credit: Source link

26 Aug

Continuous positive airway pressure (CPAP) may be a preferred alternative to noninvasive ventilation (NIV) as first-line therapy in stable ambulatory patients with obesity hypoventilation syndrome (OHS) and concurrent severe obstructive sleep apnea (OSA), as suggested by study results published in the Annals of the American Thoracic Society.

Despite the conclusions of this study, the investigators indicated that NIV and CPAP exhibit comparable efficacy profiles in this patient population. The study was a literature review conducted to inform an international panel of experts on the development of an OHS clinical practice guideline funded by the American Thoracic Society. Research studies published between January 1946 and March 2019 that compared NIV and CPAP in patients with OHS were included in the review.

Credit: Source link

25 Aug

SaniBot uses transducer-generated ultrasound, water, and disinfectant tablets to sanitize and disinfect CPAP masks and hoses in patients’ homes.

According to the manufacturer, the ultrasound and cleansing fizzing bubbles get into small crevices that ultraviolet light can’t reach and avoids the wait times for use linked to ozone-based cleaning devices.

To use, fill the stainless steel tank with water, add a cleansing tablet (included), submerge the mask, and set the 1-30 minute timer. When the cycle is complete, remove, drain, and dry.

SaniBot is available in 4 models and is compatible with a wide range of mask types. Tank sizes vary by model. Depending on size of mask, hoses may need to be cleaned separately.

Credit: Source link

23 Jul

Enrollment has begun in the SARAH Study, an investigation of real-world disease alleviation for patients with obstructive sleep apnea (OSA). The study is based upon the “SARAH” Index, a sleep adjusted residual apnea-hypopnea index that provides a formula to measure treatment effectiveness taking into account not only efficacy under ideal circumstances but also compliance in real-world circumstances.

This SARAH Study is designed to test these differences for CPAP and oral appliances.

“The Effective AHI (SARAH index) tells the real story of how well an OSA therapy is working in the real world with patients. McEvoy demonstrated the impact of adherence on outcomes; we need this research to help us match the best therapy, considering adherence, for our patients,” says board certified sleep physician and cardiologist Lee A. Surkin, MD, in a release. Surkin is president of Empire Sleep Medicine in New York, where patients in this study are being enrolled.

“OSA is not a disease that is cured with a single night test,” says Dave Kuhns, chief science officer for ProSomnus, whose oral appliances will be used in the study. “ProSomnus devices are designed to make it easy and comfortable for patients with OSA to integrate oral appliance device therapy into their everyday lives. We look forward to the results of this important study.”

Enrollees diagnosed with OSA and prescribed oral appliances will be treated by Barry Chase, DDS, DABDSM, of Chase Dental Sleep Care. He says, “The ProSomnus Sleep Devices enable excellent outcomes. Equipping patients with a Fitbit wearable and communicating performance will help facilitate the study endpoints and could serve as a template for future treatment protocols.”

The goals of the SARAH Study resonate with Dimitry Kargman, CEO of diagnostic-treatment company iSLeep Program, which is also a partner for this study. He says, “Treating our patients with the best outcomes and maintaining that success is our top priority.”

The SARAH Study is registered under Advarra IRB #Pro00031277.

Credit: Source link

ads by google